Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer

M. Deraco, D. Baratti, B. Laterza, M. R. Balestra, E. Mingrone, Antonio MacRì, S. Virzì, F. Puccio, P. S. Ravenda, S. Kusamura

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Favorable oncological outcomes have been reported in several trials with the introduction of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the treatment of Advanced Epithelial Ovarian Cancer (EOC). However most of the studies testing the combined approach are observational and have been conducted in inhomogeneous series so that the evidence supporting the performance of this combined treatment is still poor. Median Overall and Disease Free Survivals of up to 64 months and 57 months, respectively have been reported. Although a rate of morbidity of up to 40% has been observed in some series the CRS + HIPEC continues to gain an increased popularity. Several prospective randomized trials are ongoing using the procedure in various time points of the disease. In this review several issues such as the impact of cytoreduction and residual disease (RD) on outcomes as well as the role of HIPEC will be updated from the literature evidence. Some controversial points HIPEC related will also be discussed. Recent experiences regarding the introduction of a more aggressive surgical approach to upper abdomen to resect peritoneal carcinomatosis (PC) allowed increased rates of optimal cytoreduction and has demonstrated an apparent better outcome. This evidence associated with the positive results phase III trial testing normothermic intraperitoneal as first-line chemotherapy is guiding some investigators to propose the CRS + HIPEC in the primary setting. Several prospective phase II and III trials have recently been launched to validate the role of the combined treatment in various time points of disease natural evolution.

Original languageEnglish
Pages (from-to)4-9
Number of pages6
JournalEuropean Journal of Surgical Oncology
Volume37
Issue number1
DOIs
Publication statusPublished - Jan 2011

Fingerprint

Standard of Care
Drug Therapy
Therapeutics
Abdomen
Disease-Free Survival
Ovarian epithelial cancer
Research Personnel
Morbidity
Carcinoma

Keywords

  • Cytoreductive surgery
  • Epithelial ovarian cancer
  • Hyperthermic intraperitoneal chemotherapy
  • Peritoneal carcinomatosis
  • Peritonectomy

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer. / Deraco, M.; Baratti, D.; Laterza, B.; Balestra, M. R.; Mingrone, E.; MacRì, Antonio; Virzì, S.; Puccio, F.; Ravenda, P. S.; Kusamura, S.

In: European Journal of Surgical Oncology, Vol. 37, No. 1, 01.2011, p. 4-9.

Research output: Contribution to journalArticle

@article{91c03c9e1492430faf12d10e23dda7d0,
title = "Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer",
abstract = "Favorable oncological outcomes have been reported in several trials with the introduction of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the treatment of Advanced Epithelial Ovarian Cancer (EOC). However most of the studies testing the combined approach are observational and have been conducted in inhomogeneous series so that the evidence supporting the performance of this combined treatment is still poor. Median Overall and Disease Free Survivals of up to 64 months and 57 months, respectively have been reported. Although a rate of morbidity of up to 40{\%} has been observed in some series the CRS + HIPEC continues to gain an increased popularity. Several prospective randomized trials are ongoing using the procedure in various time points of the disease. In this review several issues such as the impact of cytoreduction and residual disease (RD) on outcomes as well as the role of HIPEC will be updated from the literature evidence. Some controversial points HIPEC related will also be discussed. Recent experiences regarding the introduction of a more aggressive surgical approach to upper abdomen to resect peritoneal carcinomatosis (PC) allowed increased rates of optimal cytoreduction and has demonstrated an apparent better outcome. This evidence associated with the positive results phase III trial testing normothermic intraperitoneal as first-line chemotherapy is guiding some investigators to propose the CRS + HIPEC in the primary setting. Several prospective phase II and III trials have recently been launched to validate the role of the combined treatment in various time points of disease natural evolution.",
keywords = "Cytoreductive surgery, Epithelial ovarian cancer, Hyperthermic intraperitoneal chemotherapy, Peritoneal carcinomatosis, Peritonectomy",
author = "M. Deraco and D. Baratti and B. Laterza and Balestra, {M. R.} and E. Mingrone and Antonio MacR{\`i} and S. Virz{\`i} and F. Puccio and Ravenda, {P. S.} and S. Kusamura",
year = "2011",
month = "1",
doi = "10.1016/j.ejso.2010.11.004",
language = "English",
volume = "37",
pages = "4--9",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer

AU - Deraco, M.

AU - Baratti, D.

AU - Laterza, B.

AU - Balestra, M. R.

AU - Mingrone, E.

AU - MacRì, Antonio

AU - Virzì, S.

AU - Puccio, F.

AU - Ravenda, P. S.

AU - Kusamura, S.

PY - 2011/1

Y1 - 2011/1

N2 - Favorable oncological outcomes have been reported in several trials with the introduction of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the treatment of Advanced Epithelial Ovarian Cancer (EOC). However most of the studies testing the combined approach are observational and have been conducted in inhomogeneous series so that the evidence supporting the performance of this combined treatment is still poor. Median Overall and Disease Free Survivals of up to 64 months and 57 months, respectively have been reported. Although a rate of morbidity of up to 40% has been observed in some series the CRS + HIPEC continues to gain an increased popularity. Several prospective randomized trials are ongoing using the procedure in various time points of the disease. In this review several issues such as the impact of cytoreduction and residual disease (RD) on outcomes as well as the role of HIPEC will be updated from the literature evidence. Some controversial points HIPEC related will also be discussed. Recent experiences regarding the introduction of a more aggressive surgical approach to upper abdomen to resect peritoneal carcinomatosis (PC) allowed increased rates of optimal cytoreduction and has demonstrated an apparent better outcome. This evidence associated with the positive results phase III trial testing normothermic intraperitoneal as first-line chemotherapy is guiding some investigators to propose the CRS + HIPEC in the primary setting. Several prospective phase II and III trials have recently been launched to validate the role of the combined treatment in various time points of disease natural evolution.

AB - Favorable oncological outcomes have been reported in several trials with the introduction of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the treatment of Advanced Epithelial Ovarian Cancer (EOC). However most of the studies testing the combined approach are observational and have been conducted in inhomogeneous series so that the evidence supporting the performance of this combined treatment is still poor. Median Overall and Disease Free Survivals of up to 64 months and 57 months, respectively have been reported. Although a rate of morbidity of up to 40% has been observed in some series the CRS + HIPEC continues to gain an increased popularity. Several prospective randomized trials are ongoing using the procedure in various time points of the disease. In this review several issues such as the impact of cytoreduction and residual disease (RD) on outcomes as well as the role of HIPEC will be updated from the literature evidence. Some controversial points HIPEC related will also be discussed. Recent experiences regarding the introduction of a more aggressive surgical approach to upper abdomen to resect peritoneal carcinomatosis (PC) allowed increased rates of optimal cytoreduction and has demonstrated an apparent better outcome. This evidence associated with the positive results phase III trial testing normothermic intraperitoneal as first-line chemotherapy is guiding some investigators to propose the CRS + HIPEC in the primary setting. Several prospective phase II and III trials have recently been launched to validate the role of the combined treatment in various time points of disease natural evolution.

KW - Cytoreductive surgery

KW - Epithelial ovarian cancer

KW - Hyperthermic intraperitoneal chemotherapy

KW - Peritoneal carcinomatosis

KW - Peritonectomy

UR - http://www.scopus.com/inward/record.url?scp=78650284840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650284840&partnerID=8YFLogxK

U2 - 10.1016/j.ejso.2010.11.004

DO - 10.1016/j.ejso.2010.11.004

M3 - Article

C2 - 21112721

AN - SCOPUS:78650284840

VL - 37

SP - 4

EP - 9

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 1

ER -